Ann Otol Rhinol Laryngol:含有洋甘菊液体提取物的等渗海水鼻腔喷雾剂与其他等渗海水洗鼻液治疗过敏性鼻炎的比较

2021-07-12 AlexYang MedSci原创

包括过敏性鼻炎(AR)的特应性疾病很常见,特别是在发达国家。据估计,全世界慢性鼻炎的发病率在10%至40%之间。AR对生活质量有很大影响。此外,由AR引起的生产力下降和劳动损失也导致了严重的经济损失。

包括过敏性鼻炎(AR)的特应性疾病很常见,特别是在发达国家。据估计,全世界慢性鼻炎的发病率在10%至40%之间。AR对生活质量有很大影响。此外,由AR引起的生产力下降和劳动损失也导致了严重的经济损失。例如,美国的AR和过敏性结膜炎的费用估计每年超过60亿美元。 近期,有研究人员通过与其他等渗性海水洗鼻液的比较,阐释了含有洋甘菊液体提取物的等渗性海水喷雾对过敏性鼻炎患者的症状和鼻粘膜清除的效果。 研究包括了123名患者。根据过敏性鼻炎及其对哮喘的影响指南,对所有诊断为过敏性鼻炎的患者一开始进行糠酸莫米松鼻腔喷雾治疗。在此治疗的基础上,A组加入了含有洋甘菊液体提取物的等渗海水喷雾,B组加入了等渗海水喷雾,C组加入了等渗海水鼻腔冲洗,第四组(D组)只给予鼻腔类固醇喷雾,不进行鼻腔冲洗治疗。所有患者在治疗前后都进行了SNOT-22,并通过糖精试验测量了鼻腔粘膜清除时间。 结果发现,治疗前后的鼻粘膜清除时间和SNOT-22得分存在差异。在A、B、C和D组,SNOT-22的差异具有统计学显著意义(分别为P≤0.001;P≤0.001;P≤0.001和P=0.048)。另外,只有A组和B组的鼻粘膜清

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2047431, encodeId=b0d4204e431c2, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Wed Aug 25 03:54:47 CST 2021, time=2021-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1994960, encodeId=28ab199496060, content=<a href='/topic/show?id=eb8f10351e38' target=_blank style='color:#2F92EE;'>#鼻腔喷雾#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103517, encryptionId=eb8f10351e38, topicName=鼻腔喷雾)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a19115, createdName=stfoxst, createdTime=Fri Apr 22 01:54:47 CST 2022, time=2022-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008704, encodeId=82671008e04a2, content=学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4b085574564, createdName=ms5000001187450512, createdTime=Tue Aug 17 14:31:13 CST 2021, time=2021-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1465892, encodeId=d2bb146589267, content=<a href='/topic/show?id=736b103508c6' target=_blank style='color:#2F92EE;'>#鼻腔#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103508, encryptionId=736b103508c6, topicName=鼻腔)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=224e6763385, createdName=mnda, createdTime=Wed Jul 14 13:54:47 CST 2021, time=2021-07-14, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2047431, encodeId=b0d4204e431c2, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Wed Aug 25 03:54:47 CST 2021, time=2021-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1994960, encodeId=28ab199496060, content=<a href='/topic/show?id=eb8f10351e38' target=_blank style='color:#2F92EE;'>#鼻腔喷雾#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103517, encryptionId=eb8f10351e38, topicName=鼻腔喷雾)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a19115, createdName=stfoxst, createdTime=Fri Apr 22 01:54:47 CST 2022, time=2022-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008704, encodeId=82671008e04a2, content=学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4b085574564, createdName=ms5000001187450512, createdTime=Tue Aug 17 14:31:13 CST 2021, time=2021-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1465892, encodeId=d2bb146589267, content=<a href='/topic/show?id=736b103508c6' target=_blank style='color:#2F92EE;'>#鼻腔#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103508, encryptionId=736b103508c6, topicName=鼻腔)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=224e6763385, createdName=mnda, createdTime=Wed Jul 14 13:54:47 CST 2021, time=2021-07-14, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2047431, encodeId=b0d4204e431c2, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Wed Aug 25 03:54:47 CST 2021, time=2021-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1994960, encodeId=28ab199496060, content=<a href='/topic/show?id=eb8f10351e38' target=_blank style='color:#2F92EE;'>#鼻腔喷雾#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103517, encryptionId=eb8f10351e38, topicName=鼻腔喷雾)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a19115, createdName=stfoxst, createdTime=Fri Apr 22 01:54:47 CST 2022, time=2022-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008704, encodeId=82671008e04a2, content=学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4b085574564, createdName=ms5000001187450512, createdTime=Tue Aug 17 14:31:13 CST 2021, time=2021-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1465892, encodeId=d2bb146589267, content=<a href='/topic/show?id=736b103508c6' target=_blank style='color:#2F92EE;'>#鼻腔#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103508, encryptionId=736b103508c6, topicName=鼻腔)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=224e6763385, createdName=mnda, createdTime=Wed Jul 14 13:54:47 CST 2021, time=2021-07-14, status=1, ipAttribution=)]
    2021-08-17 ms5000001187450512

    学习了!

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2047431, encodeId=b0d4204e431c2, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Wed Aug 25 03:54:47 CST 2021, time=2021-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1994960, encodeId=28ab199496060, content=<a href='/topic/show?id=eb8f10351e38' target=_blank style='color:#2F92EE;'>#鼻腔喷雾#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103517, encryptionId=eb8f10351e38, topicName=鼻腔喷雾)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a19115, createdName=stfoxst, createdTime=Fri Apr 22 01:54:47 CST 2022, time=2022-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008704, encodeId=82671008e04a2, content=学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4b085574564, createdName=ms5000001187450512, createdTime=Tue Aug 17 14:31:13 CST 2021, time=2021-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1465892, encodeId=d2bb146589267, content=<a href='/topic/show?id=736b103508c6' target=_blank style='color:#2F92EE;'>#鼻腔#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103508, encryptionId=736b103508c6, topicName=鼻腔)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=224e6763385, createdName=mnda, createdTime=Wed Jul 14 13:54:47 CST 2021, time=2021-07-14, status=1, ipAttribution=)]
    2021-07-14 mnda

相关资讯

J Allergy Clin Immunol Pract:产前维生素D与儿童早期气源性过敏原致敏和过敏性鼻炎的关系

维生素D具有免疫调节作用,可能对过敏性疾病的发展具有重要作用,也许早在胎儿发育的前三个月就开始起作用了。研究表明,母体的维生素D可以自由穿过胎盘,其水平可以通过母体的饮食和补充来改变。维生素D的缺乏已

梅斯呼吸疾病进展(第007期)

往期参见:梅斯呼吸疾病进展(第006期)

Int J Biol Sci:Livin与Ras的协同作用诱导并维持气道粘膜的皮质类固醇抗性

有许多疾病,如慢性肺部疾病、慢性肾脏疾病、炎症性肠病、类风湿性关节炎等,都依赖于对非特异性抑制炎症有强烈作用的类固醇治疗。为了控制症状,类固醇治疗通常需要很长的时间,有些病人甚至需要终生使用。在这些病

World Allergy Organ J:现实生活中对皮下免疫疗法的坚持:COVID-19大流行的时代的变化

过敏原免疫疗法(AIT)必须持续3年才能达到长期的调节效果。坚持是确保疗效的关键。

Int Forum Allergy Rhinol:下鼻甲缩小术在小儿患者中的疗效:前瞻性分析

在非过敏性和过敏性鼻炎的情况下,慢性鼻塞是小儿耳鼻喉科的一个常见表现。对于一大部分对过敏原逃避和最大限度的药物和鼻内治疗都没有反应的病人来说,腺样体切除术历来被认为是解决慢性鼻炎的一线手术治疗方法,以

ORL J Otorhinolaryngol Relat Spec:过敏性鼻炎中鼻内类固醇的使用和满意度研究

过敏性鼻炎(AR)能够影响了大量的人口,特别是在年轻人中。局部基于人口的研究报告显示,根据国际共识报告所使用的定义,新加坡44%的学龄儿童患有AR,新加坡的鼻炎患病率为13.1%。在全球范围内,患病率